Company news

Immunic, Inc. news in 2023

Immunic, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dosing Regimens in Multiple Sclerosis

November 20, 2023

Immunic, Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 13, 2023

Immunic focusing on business development during Q4

November 13, 2023

Immunic to Announce Financial Results for the Third Quarter Ended September 30, 2023, and Provide Corporate Update

November 6, 2023

Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts

November 1, 2023

Immunic to Participate in Scientific and Industry Conferences in November

October 25, 2023

Immunic Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis at the United European Gastroenterology Week 2023

October 15, 2023

Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023

October 14, 2023

Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting

October 10, 2023

Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

October 8, 2023

Immunic to Participate in Scientific Conferences in October

October 3, 2023

Immunic to Participate in Industry and Investor Conferences in September

September 5, 2023

Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

August 16, 2023

Immunic, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update

August 2, 2023

Immunic to Participate in Investor and Scientific Conferences in August

July 31, 2023

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update

July 26, 2023

Immunic to Participate in Scientific and Investor Conferences in July

June 28, 2023

Immunic Therapeutics shares IMU-856 mode of action and target for gastrointestinal diseases

June 25, 2023

Immunic to Participate in Scientific and Investor Conferences in June

May 29, 2023

Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis

May 16, 2023

Immunic, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 10, 2023

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2023, and Provide Corporate Update

May 8, 2023

Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action

May 5, 2023

Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders

May 3, 2023

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D.

April 26, 2023

Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis

April 4, 2023

Immunic, Inc. Reports Year End 2022 Financial Results and Provides Corporate Update

February 22, 2023

Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023

February 21, 2023

Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2022, and Provide Corporate Update

February 15, 2023

Immunic to Host Virtual Celiac Disease R&D Day to Highlight Current Pathways for Drug Development and Unmet Medical Need

February 8, 2023

Immunic to Participate in Scientific and Investor Conferences in February

January 24, 2023

Calls in 2023

Decks in 2023